Journal of Oncology Pharmacy Practice最新文献

{"title":"Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysis.","authors":"Juri Chung, Joshua Park, Jamie Chin-Hon, Meredith Akerman, Alexander Hindenburg","doi":"10.1177/10781552251331559","DOIUrl":"https://doi.org/10.1177/10781552251331559","url":null,"abstract":"<p><p>BackgroundThrombosis is the second leading cause of death in cancer patients and treatment for thrombosis and prevention for secondary prophylaxis is anticoagulation. Low-molecular-weight heparin (LMWH) is more effective than vitamin K antagonists for the treatment of cancer-associated thromboembolism (CAT). Direct oral anticoagulants (DOACs) are non-inferior to dalteparin in treating CAT with similar major bleeding risks. Major guidelines recommend DOACs for CAT; however, data comparing individual DOACs to enoxaparin is lacking. The purpose of this study is to evaluate the efficacy and safety of DOACs compared to LMWH for CAT.MethodsA multi-site retrospective review was conducted in adult cancer patients with a CAT history who received either a DOAC (apixaban or rivaroxaban) or LMWH (enoxaparin). Primary efficacy and safety endpoints were recurrent thromboembolism and major bleeding occurrences. Secondary endpoints included time to subsequent CAT occurrence, time to first bleed event post initial CAT, and incidence of clinically relevant non-major and minor bleeding.ResultsA total of 102 patients were included in the study. There was no significant difference among the groups with respect to time to subsequent CAT (p = 0.5625). However, patients who received apixaban and rivaroxaban had a 2.39 times and 3.26 times higher risk of subsequent CAT respectively compared to those who received enoxaparin. Major bleeding rates were also not statistically significant (p = 0.465), despite enoxaparin having the highest rate at 8.8% and no rivaroxaban patients experiencing major bleeding.ConclusionNo differences were observed between rivaroxaban, apixaban, and enoxaparin in rates of recurrent venous thromboembolism (VTE) and bleeding.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251331559"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pharmacists' work procedures on cytotoxic drug surface contamination and related risks in a Romanian clinical hospital.","authors":"Sándor Szabó, Bogdan Feier, Cecilia Cristea","doi":"10.1177/10781552251330259","DOIUrl":"https://doi.org/10.1177/10781552251330259","url":null,"abstract":"<p><p>IntroductionRecent legislative amendments in Romania mandate that qualified pharmacy personnel undertake the centralized compounding of cytotoxic infusions and the handling of cytotoxic drugs. Nevertheless, numerous hospitals continue to depend on inadequately trained nursing staff to perform these critical tasks, thereby heightening the risk of contamination and procedural errors. It is imperative that compounding occurs within a designated room equipped with a laminar airflow hood and that appropriate protective equipment is utilized, adhering to stringent work procedures to mitigate associated risks. This study assesses the outcomes resulting from the implementation of these work procedures and the efficacy of closed transfer systems. Additionally, it compares surface contamination levels of cytotoxic drugs and bacterial presence prior to and following the establishment of these procedures.MethodsBefore this study, written work procedures were absent, and the application of closed transfer systems was limited. Comprehensive compounding and administration procedures were thus developed. After a two-year period of implementing these interventions, surface contamination levels were re-evaluated. Surface samples for cytotoxic drug contamination were collected on July 15, 2022, and on May 14, 2024. The presence of four cytotoxic drugs were evaluated initially and seven in the second period from six tested areas. In September 2023, microbial surface contamination inside the hood was assessed using the surface wipe method, then analysed with a commercially available bioluminescence kit and the sterility of the final compounded infusion was checked using the incubation method, using BacT/ALERT^® PF Plus culture bottles.ResultsWipe samples taken in 2022 indicate contamination with two to three drugs on all tested surfaces. Out of 24 samples collected, 10 tested negative. Contamination levels were detected for 5-fluorouracil, gemcitabine and paclitaxel on different surfaces. However, wipe samples taken in 2024 show contamination levels only for cyclophosphamide and 5-fluorouracil on two surfaces. Out of 42 samples tested, 40 were negative. Three surfaces exhibited no bacterial contamination, while one surface recorded a low level. All three compounded infusion samples for microbial contamination yielded negative results, indicating the absence of bacteria or fungi in the final infusions.ConclusionsThe findings indicate that centralized compounding performed by trained pharmacy personnel, in compliance with established work procedures, significantly reduced surface contamination levels and ensured the sterility of the compounded infusions. Similar studies must be conducted across other hospitals to enhance the understanding of contamination dynamics in the compounding of cytotoxic infusions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251330259"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia.","authors":"Rachel J Bailen, Monica I Aasum, Linda M Tamminga, Amber B Koehler, Amy L Behnken, Jen Harden, Paul J Hampel, Yucai Wang, Eli Muchtar, Saad S Kenderian, Neil E Kay, Kari G Rabe, Wei Ding, Timothy G Call, Sameer A Parikh","doi":"10.1177/10781552251323195","DOIUrl":"https://doi.org/10.1177/10781552251323195","url":null,"abstract":"<p><p>PurposeVenetoclax-based treatment for chronic lymphocytic leukemia (CLL) can be a logistically burdensome regimen due to extensive required monitoring of tumor lysis syndrome (TLS). The purpose of this study was to evaluate the feasibility and safety of pharmacist and registered nurse (RN) driven management of venetoclax ramp-up in CLL.MethodsThis was a prospective, pilot program for patients receiving venetoclax-based therapy for CLL. Patients had nine weekly visits during the first three cycles of therapy, of which five visits were independently performed by a pharmacist or RN. Laboratory tests to evaluate TLS were ordered and monitored independently by the RN in collaboration with clinicians (physician, nurse practitioner, physician assistant).ResultsThirty CLL patients, median age 67 years, 73% treated in the frontline setting, started venetoclax between May 2022 and January 2023. After the initial three weeks of obinutuzumab treatment, TLS risk prior to venetoclax initiation had improved to low (93%), medium (3%), and high (3%). There was zero incidence of laboratory or clinical TLS by Howard criteria during the venetoclax ramp-up for all patients. Pharmacist and RNs performed 139 independent visits and monitored 197 sets of TLS labs.ConclusionUse of independent pharmacist and RN visits for toxicity checks and TLS monitoring during weekly venetoclax dose ramp-up did not lead to increased incidence of TLS in patients with CLL. These visits increased both access and efficiency within the CLL clinic. This concept has the potential to be applied in other cancer care settings with a variety of treatment regimens.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251323195"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to complete oncology pharmacist tasks: A joint opinion of the Hematology/Oncology Pharmacy Association and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network.","authors":"Shawn P Griffin, Jessie Signorelli, Farah Raheem, Kristin Adler, Lydia L Benitez, Rose M Cheng, Emily Dotson, Marielle Fares, Beejal R Ganti, Erin Hickey Zacholski, Aubrey R Lasko, Amanda B Lewallen, Alia C Lynch, Nikola Paulic, David Quach, Vishnuprabha Vogel, Matt Yacobucci, Grazyna Riebandt","doi":"10.1177/10781552251330252","DOIUrl":"https://doi.org/10.1177/10781552251330252","url":null,"abstract":"<p><p>PurposeThe time to complete oncology pharmacist tasks is needed to determine workload and productivity. The Hematology/Oncology Pharmacy Association (HOPA) and the Hematology/Oncology Practice and Research Network (PRN) of the American College of Clinical Pharmacy (ACCP) partnered with the aim of establishing consensus on the time required to complete oncology pharmacy tasks.MethodsFifteen patient care tasks and 9 non-patient care tasks, commonly completed by oncology pharmacists were each assigned an average amount of time to be completed. This list was then converted into 24 statements and the Delphi survey method was utilized with an expert panel to arrive at consensus between December 2023 and February 2024. Consensus was defined as at least 75% agreement. The complete manuscript was endorsed by HOPA and ACCP Hematology/Oncology PRN.ResultsThirty-three pharmacist-experts agreed to participate in this survey with all participating in round 1, and 29 (87.9%) participating in round 2. In round 1, 9 tasks achieved consensus, with 7 of these being classified as patient care associated. Seven statements reaching 65% but less than 75% agreement were deemed to reach borderline consensus. Eight statements failed to achieve at least 65% agreement and were modified based on respondent feedback. In round 2, 15 statements were included with all achieving consensus. At the completion of round 2, all 24 statements reached consensus, and the survey was deemed complete.ConclusionThis project produced the first comprehensive consensus statements for the average time for a US-based oncology pharmacist to complete common patient and non-patient care-related tasks.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251330252"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of consultations and interventions in a pharmacist-led outpatient clinic on duration of treatment and adverse events with osimertinib.","authors":"Sumiyo Tsukiyama, Ikuto Tsukiyama, Haruna Sugita, Masafumi Ohnishi, Hiroyuki Tanaka, Akihito Kubo, Satoru Ito","doi":"10.1177/10781552251330249","DOIUrl":"https://doi.org/10.1177/10781552251330249","url":null,"abstract":"<p><p>PurposeOsimertinib, which is a key treatment for patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer (EGFR mt NSCLC), causes intractable adverse events for some patients. The objective of this study was to assess the impact of pharmacist consultation in a pharmacist-led outpatient clinic (PLOC) and the effectiveness of pharmacist interventions on osimertinib treatment.Patients and MethodsThis observational cohort study included patients who started osimertinib for EGFR mt NSCLC at Aichi Medical University Hospital between April 2018 and December 2021. The duration of treatment and occurrence of adverse events were compared according to whether they consulted a PLOC pharmacist, and whether they received pharmacist intervention. This study was approved by the ethical review board of the university (approval no. 2019-203).ResultsThe median duration of treatment was significantly longer for the patients who consulted with the PLOC pharmacist than for those who did not (561 vs 203 days, hazard ratio 0.40, <i>p</i> < 0.001). The median duration of treatment was significantly longer for patients who received pharmacist intervention than for those who did not. (774 vs 237 days, hazard ratio 0.39, <i>p</i> < 0.001). The discontinuation rate was significantly lower in patients who consulted a PLOC pharmacist than for those who did not (73% vs 97%, <i>p</i> = 0.008). However, the rates and reason for osimertinib discontinuation or dose reduction did not differ between groups.ConclusionPLOC consultation and intervention for the treatment of adverse events might have led to extending the duration of osimertinib treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251330249"},"PeriodicalIF":1.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective analysis of efficacy of dexamethasone-sparing antiemetic regimens in high and moderate emetogenic chemotherapy.","authors":"Naveenraj Viswanathan, Harish Kamaraj, Ardhra Jiju, R V Viknesh, Ram Abhinav Kannan, Velusamy Premsundari","doi":"10.1177/10781552251330811","DOIUrl":"https://doi.org/10.1177/10781552251330811","url":null,"abstract":"<p><p>ObjectivesMultiple moderate-to-severe side effects associated with dexamethasone (DEX) were observed by patients undergoing a multi-day DEX regimen for delayed chemotherapy-induced nausea and vomiting (CINV). Therefore, there is increasing demand in clinical practice to lower DEX doses in subsequent emetogenic treatment cycles. This study aimed to evaluate the efficacy of the DEX-sparing antiemetic regimens in high- and moderate- emetogenic chemotherapy (HEC, MEC respectively) and to explore its functional impact on health-related Quality of Life (QoL).Materials and methodsThis is a prospective, observational study that includes 91 patients who received HEC and MEC with DEX. We evaluated the percentage of complete response and complete control of CINV in acute phases (<24 h) and delayed phases (25-120 h). The Functional Living Index-Emesis (FLIE), a 5-day recall tool, was used to evaluate the functional impact of DEX-sparing regimens on health-related QoL. Nausea and vomiting were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.Statistical analysisThe SPSS version 20.0 was used for the statistical analysis. In the descriptive analysis, the study's parameters were analyzed and their mean (±SD), percentage, and frequency were determined.ResultsIn terms of overall efficacy, the DEX sparing was 86.36% in complete control and 90.91% in complete response. In the CTCAE version 5.0 analyses, only 1.1% of cases were reported with a Grade 3, and none with a Grade 4 or Grade 5. The FLIE score was above 54 in each domain, indicating no impact of CINV on daily life.ConclusionThe use of DEX-sparing antiemetic regimens in clinical settings, which can be better tolerated by patients, is made clear by this study. Consequently, our findings guide clinicians to optimize the use of DEX to preserve anti-emetic efficacy throughout the scheduled cycles of emetogenic chemotherapy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251330811"},"PeriodicalIF":1.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements and challenges in CAR T cell therapy for pediatric brain tumors: A review.","authors":"Yasmina Gaoual, Adam Mahyaoui, Lamyae Yachi, Mustapha Bouatia, Zineb Aliat, Younes Rahali","doi":"10.1177/10781552251331609","DOIUrl":"https://doi.org/10.1177/10781552251331609","url":null,"abstract":"<p><p>Chimeric Antigen Receptor (CAR) T cell therapy represents a groundbreaking advancement in immunotherapy, initially gaining FDA approval for treating hematological malignancies. This therapy has shown promising results in solid tumors, particularly in pediatric brain tumors, which are the leading cause of cancer-related death in children. CAR T cells are engineered to target specific antigens on tumor cells, thereby reducing off-target effects and increasing the cytotoxic impact on cancer cells. Over the years, CAR T cell technology has evolved through five generations, each enhancing the structure, functionality, and safety of these cells. Despite these advancements, the application of CAR T cells in solid tumors, especially within the central nervous system (CNS), faces significant challenges. These include the physical barrier posed by the blood-brain barrier (BBB), the immunosuppressive tumor microenvironment (TME), and the heterogeneity of tumor antigens. The review discusses several promising antigenic targets for CAR T cells in pediatric brain tumors, such as HER2, EphA2, IL-13Rα2, and Survivin, which have been explored in recent clinical trials. These trials have shown early promise in improving patient outcomes, though the risks of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain concerns. The future of CAR T cell therapy lies in overcoming these barriers through innovative approaches like \"Armored CARs\" or TRUCKs, designed to modulate the TME and improve CAR T cell efficacy in solid tumors. Additionally, combination therapies and safety switches in next-generation CAR T cells are being explored to enhance therapeutic potential while minimizing adverse effects.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251331609"},"PeriodicalIF":1.0,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent developments on checkpoint inhibitors, CAR T cells, and beyond for T cell-based immunotherapeutic strategies against cancer.","authors":"Shaukat Ali, Mahnoor Arshad, Muhammad Summer, Maryam Zulfiqar, Shehzeen Noor, Laiba Nazakat, Muhammad Abdullah Javed","doi":"10.1177/10781552251324896","DOIUrl":"https://doi.org/10.1177/10781552251324896","url":null,"abstract":"<p><p>ObjectiveThere was a dire need to construct a review of the recent developments on Immune checkpoint inhibitors (ICIs), CAR T Cells, and other approaches for T cell-based immunotherapeutic strategies against cancer as cancer has become one of the most fatal diseases that is responsible for causing several deaths per annum.Data sourcesMultiple published data was acquired from the high-impact factor journal articles.Data summaryMultiple clinical strategies have been in use today such as radiotherapy, chemotherapy and immunotherapy to treat cancer of different types. Among novel cancer management strategies, the role of cancer immunotherapy by T cells has become immensely important. Cancer immunotherapy has revolutionized treatment approaches and it basically utilizes the body's immune system to treat cancer. At the forefront of this revolution, T cells are considered as the fundamental components of immune system.ConclusionsThe current review explores the therapeutic potential of T cells in the fight against cancer by applying strategies such as various ICIs (PD-1/PD-L1, CTLA-4, TIGIT, BTLA, TIM3, LAG3) and adoptive cell therapy. ICIs stimulate the body's existing anti-tumor T-cell response by the way of removing immune system inhibitors. On the other hand, in adoptive cell therapy (ACT) patient's T cells are modified to identify and attack tumor cells. Furthermore, this review also highlights significant successes that are observed with these therapies, notably PD-1 blockade and CAR T-cell therapy for various tumors. Moreover, this review also explores the potential of therapeutic vaccination, bispecific antibodies and cytokine therapy to enhance the antitumor activity. Therapeutic vaccines expose immune system to various tumor-associated antigens and training it to identify and then attack cancer cells, showing promising results in different types of cancers such as prostate cancer and melanoma. While, cytokine therapy is accompanied by the use of cytokines such as interleukin-2 (IL-2) to stimulate immune cell activity and proliferation, thereby boosting the overall anti-tumor immune response. Lastly, the current review explores the promising future of T cell-based immunotherapy, envisioning advancements in CAR design and gene editing techniques that can enhance efficacy across a broader spectrum of cancers.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251324896"},"PeriodicalIF":1.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated definition and components for oncology stewardship in healthcare systems.","authors":"Nabin Pathak, Simit Sapkota, Grace Wangge, Adeel Siddiqui, Sunil Shrestha","doi":"10.1177/10781552251330241","DOIUrl":"https://doi.org/10.1177/10781552251330241","url":null,"abstract":"<p><p>Limited studies discuss the updated definition and essential components of oncology stewardship. In this paper, we aim to present a revised definition of oncology stewardship emphasizing its broader application across multiple cancer therapies, including systemic chemotherapy, immunotherapy, targeted treatments and newer therapies associated with cancer care. We outline essential elements required for its implementation, which may vary between high-income and low-middle-income countries depending on available resources. Regardless of the setting, key components include adherence to evidence-based clinical practice guidelines, continuous quality improvement, cost-effectiveness strategies, a multidisciplinary team approach, and prioritization of patient-centered care.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251330241"},"PeriodicalIF":1.0,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of sunscreen in the prevention of skin cancer.","authors":"John P Micha, Randy D Bohart, Bram H Goldstein","doi":"10.1177/10781552251327596","DOIUrl":"https://doi.org/10.1177/10781552251327596","url":null,"abstract":"<p><p>ObjectiveDespite the reported benefits of sunscreen use in preventing skin cancer, the overall protection from melanoma and non-melanoma skin cancers putatively reflects the frequency of use and sunscreen type. Herein, we review the current knowledge regarding sunscreen's effectiveness at averting the development of skin cancers.Data sourcesWe conducted an extensive PubMed search comprising several review articles on the topic of sunscreen use and prevention of skin cancer, with specific terms that included sunscreen and usage, skin cancer, and sunscreen side effects.Data summarySeveral observational, cohort studies and randomized controlled trials have underscored the benefits of sunscreen in forestalling skin cancers. In particular, the incidence of melanoma and squamous-cell carcinoma is reduced, although the effect of sunscreen on basal-cell carcinoma is relatively less pronounced.ConclusionsThe implications from this study indicate that sunscreen reduces the incidence of melanoma and non-melanoma skin cancers although deriving the intended effect is contingent upon the type of sunscreen and adherence to the recommended guidelines. The primary side effects from sunscreen include dermal irritation and rash; and since there is some indication that UV filter-based sunscreens may harbor carcinogenic properties, clinicians should advise their patients on the type of sunscreen, not to mention the frequency of use.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251327596"},"PeriodicalIF":1.0,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143692613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}